Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma

Published:2012-09-14 Issue:11 Volume:103 Page:1979-1984
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Chen Yongshun¹,Wu Xiaoyuan¹,Bu Shanshan¹,He Chunyu¹,Wang Wen¹,Liu Jinsong¹,Guo Wei¹,Tan Bo¹,Wang Yanxia²,Wang Jianhua¹

Affiliation:

1. Division of Radiation Oncology; Henan Tumor Hospital, Zhengzhou University Affiliated Tumor Hospital; Zhengzhou; China

2. Division of Radiation Oncology; Central Hospital of Jiaozuo Coal Group; Jiaozuo; China

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2012.02393.x/fullpdf

Reference34 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Cancer trends in China;Zhao;Jpn J Clin Oncol,2010

3. Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities;Mariette;Lancet Oncol,2007

4. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospectice randomized trial (RTOG 85-01);Cooper;JAMA,1999

5. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus;Wong;Cochrane Database Syst Rev,2006

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial;British Journal of Cancer;2023-10-20

2. Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study;Clinical and Translational Radiation Oncology;2023-01

3. Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial;The Innovation;2022-05

4. Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma;Cancer Biology & Medicine;2022-01-12

5. A novel immune-related gene signature predicts survival in esophageal squamous cell carcinoma;Translational Cancer Research;2021-05